Merck concludes acquisition of Acceleron Pharma
Kenilworth: Merck, known as MSD outside the United States and Canada, has recently announced the successful completion of the acquisition of Acceleron Pharma Inc.
"This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy," said Rob Davis, chief executive officer and president, Merck. "Fueled by Acceleron's groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need."
Read also: Dr Reddys open to making Pfizer COVID pill after deal with Merck
Acceleron is focused on harnessing the power of the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron's therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Sotatercept is in Phase 3 trials as add-on to current standard of care for the treatment of PAH.
Read also: Merck Keytruda gets USFDA nod as adjuvant kidney cancer treatment
